UK markets closed
NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,284.54 +83.27 (+0.48%) CRUDE OIL
82.59 -0.22 (-0.27%) GOLD FUTURES
2,341.60 +3.20 (+0.14%) DOW
37,983.32 -477.60 (-1.24%) Bitcoin GBP
51,434.50 -233.54 (-0.45%)
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 12:52PM EDT. Market open.
| Previous close | 67.08 |
| Open | 66.59 |
| Bid | 65.51 x 300 |
| Ask | 65.58 x 300 |
| Day's range | 65.32 - 67.90 |
| 52-week range | 65.32 - 87.87 |
| Volume | |
| Avg. volume | 7,193,293 |
| Market cap | 81.739B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 14.57 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (4.59%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Zacks
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
- Zacks
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
© 2024 Yahoo. All rights reserved.